NattoPharma says that the patent gives it “broad coverage” in the use of vitamin K2, also known as menaquinones, in these types of products.
NattoPharma ASA (Oslo, Norway) has obtained a U.S. patent covering the use of vitamin K2 in food products, including dietary supplements, for the purpose of “maintaining, optimizing, strengthening, or promoting cardiovascular health,” the company reports.
NattoPharma says that the patent gives it “broad coverage” in the use of vitamin K2, also known as menaquinones, in these types of products.
“The approval of the patent represents a milestone for NattoPharma and our partners in the U.S. market,” says company CEO Hogne Vik, PhD. “This will strengthen NattoPharma’s global IPR-platform and improve our competitive position in the United States within the food supplement market as well as the functional food market.”
The patent is No. 09/850,804: “Vitamin K2 Containing Food Product.” NattoPharma is the supplier of branded vitamin K2 ingredient MenaQ7.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.